Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A

被引:37
作者
Busche, A
Goldmann, T
Naumann, U
Steinle, A
Brandau, S
机构
[1] Res Ctr Borstel, Dept Clin Med, Div Clin & Expt Pathol, D-23845 Borstel, Germany
[2] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Gen Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany
[3] Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany
[4] Res Ctr Borstel, Dept Immunol & Cell Biol, Div Immunotherapy, D-23845 Borstel, Germany
关键词
D O I
10.1089/hum.2006.17.135
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Studies have highlighted molecular and cell biological mechanisms of the NKG2D-NKG2D ligand system in the activation of natural killer (NK) cell and T cell functions. In this study we explore the potential of genetic overexpression of human major histocompatibility complex class I chain-related gene A ( MICA), a powerful NKG2D ligand, for the induction of NK cell-mediated antitumor immunity in a humanized murine model of non-small cell lung cancer. Using tissue microarray technology we detected expression of MICA in only 30% of the samples from patients with lung cancer. Staining was always weak and focal, indicating that expression of MICA is detectable but limited in human lung cancer. Genetic overexpression of MICA by means of adenoviral transduction or transfection of expression plasmids was feasible in cell lines in vitro, primary human cancer tissue ex vivo, and in experimental human cancers in vivo. The presence of MICA on the surface of largely NK cell-resistant human lung cancer cells reestablished NK cell susceptibility and provoked NK cell-mediated antitumor immunity by murine and human NK cells in two different experimental therapy models. In this study we analyze the interaction of human NK cells with MICA-positive human cancer cells in an in vivo setting. Our data demonstrate that MICA overexpression can function as NK cell-mediated immunotherapy in experimental lung cancer.
引用
收藏
页码:135 / 146
页数:12
相关论文
共 48 条
  • [31] Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection
    Kelly, JM
    Darcy, PK
    Markby, JL
    Godfrey, DI
    Takedo, K
    Yagita, H
    Smyth, MJ
    [J]. NATURE IMMUNOLOGY, 2002, 3 (01) : 83 - 90
  • [32] KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-γ production
    Kikuchi-Maki, A
    Yusa, S
    Catina, TL
    Campbell, KS
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (07) : 3415 - 3425
  • [33] Turning on natural killer cells
    Lanier, LL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (08) : 1259 - 1262
  • [34] High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-"pan" RAE-1 antibody confer tumor susceptibility to NK cells
    Masuda, H
    Saeki, Y
    Nomura, M
    Shida, K
    Matsumoto, M
    Ui, M
    Lanier, LL
    Seya, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (01) : 140 - 145
  • [35] MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal
    Menier, C
    Riteau, B
    Carosella, ED
    Rouas-Freiss, N
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (01) : 63 - 70
  • [36] NF-kB regulates expression of the MHC class I-related chain A gene-in activated T lymphocytes
    Molinero, LL
    Fuertes, MB
    Girart, MV
    Fainboim, L
    Rabinovich, GA
    Costas, MA
    Zwirner, NW
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (09) : 5583 - 5590
  • [37] LYMPHOCYTES IN THE LUNG - AN OFTEN NEGLECTED CELL - NUMBERS, CHARACTERIZATION AND COMPARTMENTALIZATION
    PABST, R
    TSCHERNIG, T
    [J]. ANATOMY AND EMBRYOLOGY, 1995, 192 (04): : 293 - 299
  • [38] Pende D, 2002, CANCER RES, V62, P6178
  • [39] Robertson MJ, 1996, EXP HEMATOL, V24, P406
  • [40] Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer:: Results of a multicenter phase II study
    Schuler, M
    Herrmann, R
    De Greve, JLP
    Stewart, AK
    Gatzemeier, U
    Stewart, DJ
    Laufman, L
    Gralla, R
    Kuball, J
    Buhl, R
    Heussel, CP
    Kommoss, F
    Perruchoud, AP
    Shepherd, FA
    Fritz, MA
    Horowitz, JA
    Huber, C
    Rochlitz, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1750 - 1758